α6β4 nAChR agonist (Rapport Therapeutics)

N/A

Report date: 2026/01/28 17:56:20
NME

Base Information

Drug Nameα6β4 nAChR agonist (Rapport Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNicotinic acetylcholine receptor alpha 6 modulatorsBeta-4 nicotinic acetylcholine receptor agonists
TargetsNicotinic acetylcholine receptor alpha 6Beta-4 nicotinic acetylcholine receptor
Therapy Area/IndicationsChronic PainMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRapport Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRapport Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsChronic PainMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A